Navlin Daily: U.S. Pharma & Biotech Summit 2026: How Will the FDA Adapt to the Rise of China?

The U.S. biotech industry is facing a major global rival for the first time. In response to the Chinese life science industry’s rapid growth, U.S. policymakers and regulators are racing to support Western innovation while maintaining patient safety.